YL-17231

pan-RAS inhibitor · Shanghai YingLi Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YL-17231, covering 2025-04-09 to 2025-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS [Phase 1]

See pricing